\nStrategic Leadership Addition Signals Drive to Expand Diagnostics Business<\/i><\/p>
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX)<\/b>, a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the appointment of Geoff Albrecht as Senior Vice President and General Manager of Diagnostics. This strategic hire underscores Quanterix\u2019s commitment to transforming its Diagnostics opportunity into a key component of the company\u2019s future growth strategy.<\/p>
\nStarting with Alzheimer\u2019s Disease Diagnostics, Albrecht will lead the company\u2019s Diagnostics strategy and the development of a comprehensive infrastructure and operational framework necessary to scale Quanterix\u2019s Diagnostics portfolio into a significant revenue driver. He will report directly to the Chief Executive Officer and serve as a member of the Executive Leadership Team.<\/p>
\n\u201cGeoff\u2019s appointment marks a pivotal moment in Quanterix\u2019s evolution,\u201d said Chief Executive Officer Everett Cunningham. \u201cWe are making our Diagnostics business a fundamental pillar of our commercial strategy and future growth trajectory. We believe Geoff\u2019s deep experience commercializing diagnostics makes him ideally suited to make Quanterix a leader in Alzheimer\u2019s Diseases testing.\u201d<\/p>
\nAlbrecht brings more than 25 years of distinguished commercial leadership experience from Quest Diagnostics, where he served as Regional Vice President for the Northeast U.S. region, managing full profit and loss responsibility for approximately $2.9 billion in revenue. Throughout his tenure at Quest, he held multiple senior leadership positions, including Manager, Director of Sales, and Vice President of the North Region, where he successfully led business development initiatives, sales operations, joint venture partnerships, and merger and acquisition growth strategies.<\/p>
\nHis expertise spans strategic partnerships with health systems, health plans, physician outreach organizations, and employer groups. Importantly, Albrecht has demonstrated exceptional capability in executing market strategies, optimizing operational processes, and implementing metrics-driven accountability frameworks that will be critical to the success of the Company\u2019s diagnostics portfolio.<\/p>
\nIn addition to his corporate responsibilities, Albrecht served as a board member for UPMC and UMass joint venture partnerships, bringing valuable governance experience to his new role. He earned his Bachelor of Arts from Villanova University and will be based at Quanterix\u2019s Billerica, MA headquarters.<\/p>
\nAbout Quanterix<\/b><\/p>
\nQuanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa\u00ae<\/sup> technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With approximately 6,500 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company\u00ae<\/sup>, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,450 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue\u2014advancing precision medicine from discovery to diagnostics. Learn more at www.quanterix.com<\/a>.<\/p> \nCAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS<\/b><\/p> \nStatements included in this press release that are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements about Quanterix\u2019s future business operations and strategy, including statements related to our expectations about, the development and commercialization of our diagnostics business. Words and phrases such as \u201cmay,\u201d \u201capproximately,\u201d \u201ccontinue,\u201d \u201cshould,\u201d \u201cexpects,\u201d \u201cprojects,\u201d \u201canticipates,\u201d \u201cis likely,\u201d \u201clook ahead,\u201d \u201clook forward,\u201d \u201cbelieves,\u201d \u201cwill,\u201d \u201cintends,\u201d \u201cestimates,\u201d \u201cstrategy,\u201d \u201cplan,\u201d \u201ccould,\u201d \u201cpotential,\u201d \u201cpossible\u201d and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are subject to certain risks and uncertainties that are difficult to predict with regard to, among other things, timing, extent, likelihood and degree of occurrence, which could cause actual results to differ materially from anticipated results. Such risks and uncertainties include, among others, the following possibilities with respect to Quanterix\u2019s future business, operations, strategy and financial performance: risks related to the impact of changes in U.S. government policies, including impacts of tariffs and reductions in federal research funding; risks associated with the anticipated timing for launch of, and features of, Quanterix\u2019s next-generation instruments to upgrade its existing platforms; risks related to Quanterix\u2019s ability to improve existing diagnostics and develop new diagnostic tests and tools; risks related to Quanterix\u2019s ability to successfully penetrate the diagnostics market; risks related to Quanterix\u2019s ability to retain and expand its customer base and achieve sufficient market acceptance of its products; risks related to the ability of Quanterix\u2019s contract manufacturers and suppliers to reliably and consistently manufacture and supply our instruments; risks that Quanterix may fail to realize the anticipated benefits and synergies of its recent acquisitions of Emission, Inc. and Akoya Biosciences Inc.; risk that integrating Quanterix\u2019s business with that of Akoya could be more difficult, costly or time-consuming than expected; risks that Quanterix\u2019s estimates regarding expenses, future revenues, capital requirements, and needs for additional financing could be incorrect; risks related to Quanterix\u2019s ability to maintain effective internal control over financial reporting and disclosure controls and procedures; and risks related to defects or other quality issues in Quanterix\u2019s products that could lead to unforeseen costs, product recalls, adverse regulatory actions, negative publicity and litigation. Additional factors that could cause results to differ materially from those described above can be found in the periodic reports filed by Quanterix with the SEC, including the \u201cRisk Factors\u201d sections contained therein, which are available on the SEC\u2019s website at www.sec.gov<\/a>.<\/p> \nAll forward-looking statements, expressed or implied, included in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to herein. If one or more events related to these or other risks or uncertainties materialize, or if Quanterix\u2019s underlying assumptions prove to be incorrect, actual results may differ materially from what Quanterix anticipates. Quanterix cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made and are based on information available at that time. Quanterix does not assume any obligation to update or otherwise revise any forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements were made or to reflect the occurrence of unanticipated events except as required by federal securities laws.<\/p> \nMedia\n